Novartis
Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing evolving patient needs worldwide. It operates through several divisions: Novartis Pharmaceuticals for innovative medicines, Sandoz for generics and biosimilars, and Alcon for eye care devices. The company focuses on key therapeutic areas such as oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic diseases. Novartis also invests in early-stage life sciences and biotechnology companies through its venture capital arm, Novartis Venture Fund, seeking innovative therapeutics, medical devices, diagnostics, and drug delivery systems. Additionally, Novartis Animal Health develops products for pets, farm animals, and farmed fish, contributing to animal health and welfare. The company's research and development efforts are supported by the Genomics Institute of the Novartis Research Foundation, which bridges basic science and preclinical drug discovery.
Calypso Biotech
Acquisition in 2024
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.
Alcon is a leading global company in the vision care sector, headquartered in Geneva, Switzerland. Established in 1945, it specializes in developing and manufacturing innovative medical devices and pharmaceuticals focused on eye care. The company operates in two primary segments: Vision Care and Surgical. The Vision Care segment offers a range of products, including contact lenses and ocular health solutions, with well-known brands such as Dailies, Total1, and Air Optix, capturing a significant share of the U.S. contact lens market. The Surgical segment provides essential tools and devices for ophthalmic surgeries, including intraocular lenses and advanced surgical equipment like the Centurion phacoemulsification device used in cataract procedures. After operating as a subsidiary of Novartis for nine years, Alcon became an independent public company in April 2019, continuing its commitment to delivering comprehensive eye care solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.